@Bursa_advisor.. What is your advise TP? Can it go over 0.40 short term, and 0.80 mid term?

YongTai vaccine.. faster fly!

0.31.. luckily still holding some from 0.26.. 0.45 again soon please!

YT is not solely vaccine... i agree that the property side is slowly recovering. you can look at other property counter, they are gaining back so much.

isn't YT working with Kangtai? the one that produce Astra, though not the same vaccine as YT is getting...

agree... whether want to push up or not only.. look at glove counter... so much supply, still shooting limit up... vaccine counter should perform even better...

ICPS 1,000,400 units at RM0.80.. wahhhh

no idea what is happening.. good news but drop instead... market sentiment too bad already because of political news?

YT collaborate with Tiong Nam on distribution? extra one month to enter before too late?

oh.. high chance dropping? got read the latest announcement?

then i remove my comment. ha ha

politicians again?

volume banyak giler...

huhu...tak tau siapa menang siapa kalah lagi ni.

press down before fly? 92mil volume, who is buying?

jump ship or sail...

no show already? sell force too strong? big boss dunwan bilis to earn

when the vaccine deal finalized? this week or next?

so many selling.. not easy to go up.

sell more now, cry later.... :)

cannot fly because too many sellers

it won't limit up. too many sellers...

what a huge queue to sell by ikan bilis...harap diorang jgn regret nanti.. hohoho

many people stuck here it seems... keep saying something brewing or coming up.. so that ppl enter and they can exit? so naive?

good price now.. buy or else regret later.

huat now!

PP at 0.80 again..

come on baabe

power ni...

harap bukan fake rebound

making announcement soon? same like Nov end?

tak pasti tu. tengok volume dia, ada orang collect banyak ni. rugi la yang sudah jual.. jom kita fly high pi 0.40 bagi 2020..

tak tau... ini trend macam sama dengan dulu before announce vaccine... volume pun sama.

cannot goes up any more tu. power push kat atas

shoooooooooo hairy... go other place to bark.

someone took up all the sell volume at 0.285 and 0.29. wonder who and why.

no rebound. selling force too strong, operator won't pick up all unless got news coming.

too many sellers.. don't think the buyers can take up all the selling pressure.

from 0.375 to 0.5 in such short period...normal that it adjust downwards now.

wonder how many ppl got stucked here..

the crowd here seems normal compare to klscreener. People spread fake news to create fear there for panic selling.

aigogooo... 47mil volume..yet went down again..

no show day again.. everyday drop bit by bit..

hmm..why keep press down the price. 13million volume. the price still same as previous close. what magic.

looking at the number of bilis queuing to sell...not easy to achieve good price today.. too many people want to exit. haha

steady bom pipi... hope dato wira let us have a good year end

haha...6.3millions volume, but the movement is so sad.

Google Translate:
Financial Associated Press (Shenzhen, reporter Ding Rong), Malaysian listed company YONGTAIBERHAD recently announced that the company has reached cooperation with Shenzhen Kangtai Biological Products Co., Ltd. and KLINSELSDNBHD to promote Kangtai Bio-New Crown inactivated vaccine in Malaysia to carry out phase III clinical trials . After the phase III clinical trial is successfully concluded or emergency use rights are obtained in Malaysia, the company will have the exclusive commercialization rights. The two parties plan to cooperate with about 100 million doses, a five-year vaccine procurement plan.

A person close to Kangtai Biologicals (300601.SZ) said: "At present, Kangtai Biologicals Covid-19 vaccine research and development continues to advance. This time, it is cooperating with Malaysia YONGTAIBERHAD to jointly promote the international multi-center phase III clinical trial of the new coronavirus inactivated vaccine."

Regarding the new coronavirus inactivated vaccine (Vero cell), Kangtai Biotechnology received a drug clinical trial approval document issued by the National Medical Products Administration in September this year. After review and review by a special expert group, the product was approved for clinical trials in an emergency. The indication is Prevent new coronavirus pneumonia caused by new coronavirus infection. Information from the China Clinical Trial Registration Center shows that the vaccine has entered the phase II clinical trial in October.

It is worth mentioning that in addition to the independently developed inactivated vaccine for the new crown, Kangtai Biotech also cooperates with AstraZeneca in the ChAdOx1 adenovirus vector vaccine. The viral vector COVID-19 vaccine developed by the company and AstraZeneca is currently in the phase III clinical trial. It is a rapidly progressing COVID-19 vaccine project in the world. It is expected to be used urgently in Europe and the United States by the end of the year. It is expected to be introduced to China in the future. The time for domestic clinical trials is expected. It will also be shortened. In addition, Kangtai Biological also deployed recombinant VSV virus vector vaccine.

The Financial Association stated: The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.

weak bilis, strong counter.

volume so huge, yet the price did not reflect any and dropped at the very last minute. So fishy counter.